Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Willekens

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Blood Cancer Journal|April 24, 2024
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectivesDana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Journal of Blood Medicine|September 14, 2016
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesJohanna Mondesir, Christophe Willekens, Mehdi Touat, et al.
Journal of Medical Case Reports|July 5, 2011
Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case reportChristophe Willekens, Aurélie Cornelius, Mary-Jane Guerry, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer CampusAli N Chamseddine, Christophe Willekens, Stephane De Botton, et al.
Expert Review of Hematology|October 29, 2014
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factorsNicolas Duployez, Christophe Willekens, Alice Marceau-Renaut, et al.
Hemoglobin|July 21, 2010
Identification of a new mutation on the beta-globin gene: codons 8/9 (+AGAA); GAG.AAG.TCT(Glu-Lys-Ser)>GAG. AAAGAAG, in a patient from the north of France with a phenotype of beta-thalassemia minorAnne France Georgel, Claude Méreau, Christophe Willekens, et al.
Rheumatology (Oxford, England)|November 9, 2020
Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case reportMarion Corfmat, Christophe Willekens, Julien Vinit, et al.
Expert Opinion on Pharmacotherapy|April 9, 2009
Bortezomib and Waldenstrom's macroglobulinemiaLaurent Pascal, Julie Gay, Christophe Willekens, et al.
Haematologica|December 5, 2015
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trialChristophe Willekens, Odile Blanchet, Aline Renneville, et al.
American Journal of Hematology|November 28, 2014
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)Anne Quinquenel, Christophe Willekens, Jehan Dupuis, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Blood Cancer Journal|April 24, 2024
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectivesDana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Journal of Blood Medicine|September 14, 2016
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesJohanna Mondesir, Christophe Willekens, Mehdi Touat, et al.
Journal of Medical Case Reports|July 5, 2011
Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case reportChristophe Willekens, Aurélie Cornelius, Mary-Jane Guerry, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer CampusAli N Chamseddine, Christophe Willekens, Stephane De Botton, et al.
Expert Review of Hematology|October 29, 2014
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factorsNicolas Duployez, Christophe Willekens, Alice Marceau-Renaut, et al.
Hemoglobin|July 21, 2010
Identification of a new mutation on the beta-globin gene: codons 8/9 (+AGAA); GAG.AAG.TCT(Glu-Lys-Ser)>GAG. AAAGAAG, in a patient from the north of France with a phenotype of beta-thalassemia minorAnne France Georgel, Claude Méreau, Christophe Willekens, et al.
Rheumatology (Oxford, England)|November 9, 2020
Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case reportMarion Corfmat, Christophe Willekens, Julien Vinit, et al.
Expert Opinion on Pharmacotherapy|April 9, 2009
Bortezomib and Waldenstrom's macroglobulinemiaLaurent Pascal, Julie Gay, Christophe Willekens, et al.
Haematologica|December 5, 2015
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trialChristophe Willekens, Odile Blanchet, Aline Renneville, et al.
American Journal of Hematology|November 28, 2014
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)Anne Quinquenel, Christophe Willekens, Jehan Dupuis, et al.
Pageof 5